Literature DB >> 23391803

Comparison of line probe assay with liquid culture for rapid detection of multi-drug resistance in Mycobacterium tuberculosis.

Ritu Singhal, Jyoti Arora, Prabha Lal, Manpreet Bhalla, Vithal Prasad Myneeedu, Digamber Behera.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23391803      PMCID: PMC3612310     

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


× No keyword cloud information.
Sir, Timely diagnosis and prompt treatment of infectious tuberculosis (TB) cases is pivotal towards TB control. Multi-drug resistant tuberculosis (MDR-TB) defined as the resistance to at least rifampicin (RIF) and isoniazid (INH) poses grave challenge because of prolonged, limited and expensive treatment options with 10 to 30 per cent of cases resulting in failure of treatment and death12. Conventional drug susceptibility using solid medium such as Lowenstein - Jensen (L-J) is time consuming whereas liquid medium based methods such as Mycobacterial Growth Indicator Tube (MGIT) System 960 (BD Diagnostics, USA) are sensitive and faster but involve prohibitive expenditure3. Commercial line probe assays (LPA) such as INNO-LIPA Rif TB (Innogenetics, Ghent, Belgium) and Genotype MTBDR plus assay (Hain Life Sciences, GmbH, Germany) based on reverse hybridization of amplicons to immobilized membrane based probes covering wild type and common mutation sequences of rpoB and rpoB, katG, inhA respectively, have rapid turn-around time of 48 to 72 h4. In this study, the performance of the Genotype MTBDR plus assay was evaluated using MGIT 960 as gold standard. The study was conducted in Department of Microbiology, Lala Ram Sarup Institute of Tuberculosis and Respiratory Diseases, New Delhi. The Institute is a referral tuberculosis hospital and National Reference Laboratory (NRL) for Revised National Tuberculosis Control Programme (RNTCP). Suspected MDR-TB patients attending the out-patient unit are referred for rapid culture and drug susceptibility testing. The MGIT 960 liquid culture system in the Institute is accredited for susceptibility testing for first line and second line drugs by Supra National Reference Laboratory (SNRL), Antewerp, Belgium. A total of 120 smear positive sputum specimens received from 120 patients during a period of five months (October 2010 - February 2011) were processed in BSL-3 laboratory by standard N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) method5. The concentrated samples were subjected to culture and drug susceptibility of Mycobacterium tuberculosis by MGIT 9605. Final critical concentration of anti-TB drugs used was 0.1 μg/ml of INH and 1.0 μg/ml of RIF6. Following inoculation, samples were aliquoted in duplicate for DNA extraction. DNA extraction, amplification and hybridization were carried out as per manufacturer's instructions in different pre-designated, thoroughly cleaned rooms. DNA from standard strain H37Rv and molecular grade water were used as positive and negative control, respectively with every run. For any invalid results, test was repeated on DNA extracts stored at -20° C. Each sample was run in duplicate in different batches and results matched for concordance. The result of DNA strips was interpreted as resistant for RIF and INH based on absence of hybridization to any of wild type probes and/or positive hybridization signal of common mutant probes7. Twenty per cent of randomly selected DNA were sent for external proficiency testing to National JALMA Institute of Leprosy and Other Mycobacterial Diseases, Agra, which is an accredited National Reference Laboratory for LPA. In the internal quality control, 100 per cent concordance was obtained in the duplicate testing of Genotype MTBDR plus with all 120 samples yielding same result. These included 118 valid and two invalid results. The results of external proficiency testing were in 100 per cent concordance with our results. Overall concordance of RIF and INH result between Genotype MTBDR plus and MGIT 960 was found to be 96.6 and 84.7 per cent, respectively. Other studies have reported good concordance of 84.4-98.1 per cent for RIF and 87.3-90.14 per cent for INH respectively between Genotype MTBDR plus and conventional drug susceptibility tests8–10. The sensitivity, specificity, positive and negative predictive values for detection of RIF resistance by Genotype MTBDR plus was found to be 97.6, 94.4, 97.6 and 94.4 per cent respectively (Table I). High sensitivity for RIF has also been found in other studies; 98.1 per cent, (95% CI 95.9-99.1) in the meta-analysis for comparison of Genotype MTBDR and Genotype MTBDR plus assays with conventional susceptibility testing4 and 100 per cent in studies from Uganda and France79. Specificity for RIF resistance in various studies has been found to be 98.7 per cent (pooled specificity with 95% CI 97.3-99.4%), 96.1 and 100 per cent4711. In one study, specificity of detection of RIF resistance by using INNO-LiPA Rif TB compared to conventional methods was found to be 66.7 per cent12. Such variation could be due to the intrinsic limitation of the kit mentioned above.
Table I

Comparison of LPA result with MGIT 960 for RIF and INH resistance (n=118)

Comparison of LPA result with MGIT 960 for RIF and INH resistance (n=118) The sensitivity and specificity for INH resistance for Genotype MTBDR plus was found to be 83.3 and 93.8 per cent, respectively (Table I). Resistance in 17 isolates was not detected by Genotype MTBDR plus which could be due to inability of the test to detect mutation in other genes (ahpC-oxyR and ndh) conferring INH resistance. The low sensitivity of 83.3 per cent, obtained for INH in our study is in accordance to most other studies - 84.3 per cent (95% CI 76.6-89.8), 80.8 and 67 per cent479. However, some studies have found good sensitivity for INH (92.6, 93 and 95.3%, respectively)101113. The mutation patterns of RIF and INH produced by the Genotype MTBDR plus are displayed in Table II. Specific mutation could be detected in 58 of 82 (70.7%) RIF resistant isolates. Of these, 49 had mutation in codon S531L, 6 (7.3%) in D516V and 3 (3.7%) in H526D. Other reports from India and abroad have found S531L mutation to be commonest71114–16. In 24 of 82 (29.3%) RIF resistant isolates, one or more wild type probes were missing with no gain in mutant probes. These isolates are depicted as unknown (UK). Among these maximum isolates had missing WT8-10 (41.7%). In a study from South Vietnam, 66.7 per cent isolates did not have any known mutation11.
Table II

Mutation pattern of RIF (rpoB) and INH (katG & inhA) obtained from Genotype MTBDR plus assay

Mutation pattern of RIF (rpoB) and INH (katG & inhA) obtained from Genotype MTBDR plus assay In Genotype MTBDR plus, INH resistance is detected by probes of two genes; katG and inhA Among 86 INH resistant isolates, katG mutation occurred in 77 (89.5%) of isolates. Specific mutations in codon S315T1 of katG gene was found in 73 (94.8%) isolates. Remaining four had missing wild type with no gain in mutant probes. Mutations in InhA gene occurred in 15 of 86 (17.4%) INH resistant isolates. Specific InhA mutations were found in 12 of 15 (80.0%) INH resistant isolates, of which 11 had mutation in codon C15T and one in T8C (Table II). In remaining three isolates, no specific mutation band could be detected. The mutation pattern obtained was similar to other studies in this regard717. In conclusion, genotype MTBDR plus assay was found to be rapid, sensitive and specific test for routine drug susceptibility testing for diagnosis of RIF resistance which is more crucial for management of MDR-TB. All RIF resistant cases can be shifted to category IV treatment timely, thereby curtailing the spread. Larger field trials are imperative to assess the validity and usefulness of this test in field scenario if the test is deemed to play a pivotal role in tuberculosis control at national level in India.
  15 in total

1.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India.

Authors:  C Mani; N Selvakumar; S Narayanan; P R Narayanan
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

2.  rpoB gene sequencing and spoligotyping of multidrug-resistant Mycobacterium tuberculosis isolates from India.

Authors:  Naga Suresh; Urvashi Balbir Singh; Jyoti Arora; Hema Pant; Pradeep Seth; Christophe Sola; Nalin Rastogi; Jyotish Chandra Samantaray; Jitendra Nath Pande
Journal:  Infect Genet Evol       Date:  2006-04-18       Impact factor: 3.342

3.  Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-03-24       Impact factor: 17.586

4.  Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Manzour Hernando Hazbón; Michael Brimacombe; Miriam Bobadilla del Valle; Magali Cavatore; Marta Inírida Guerrero; Mandira Varma-Basil; Helen Billman-Jacobe; Caroline Lavender; Janet Fyfe; Lourdes García-García; Clara Inés León; Mridula Bose; Fernando Chaves; Megan Murray; Kathleen D Eisenach; José Sifuentes-Osornio; M Donald Cave; Alfredo Ponce de León; David Alland
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Direct application of the INNO-LiPA Rif.TB line-probe assay for rapid identification of Mycobacterium tuberculosis complex strains and detection of rifampin resistance in 360 smear-positive respiratory specimens from an area of high incidence of multidrug-resistant tuberculosis.

Authors:  Miguel Viveiros; Clara Leandro; Liliana Rodrigues; Josefina Almeida; Rosário Bettencourt; Isabel Couto; Lurdes Carrilho; José Diogo; Ana Fonseca; Luís Lito; João Lopes; Teresa Pacheco; Mariana Pessanha; Judite Quirim; Luísa Sancho; Max Salfinger; Leonard Amaral
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India.

Authors:  Noman Siddiqi; Mohammed Shamim; Seema Hussain; Rakesh Kumar Choudhary; Niyaz Ahmed; Sharmistha Banerjee; G R Savithri; Mahfooz Alam; Niteen Pathak; Amol Amin; Mohammed Hanief; V M Katoch; S K Sharma; Seyed E Hasnain
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Johanna Mäkinen; Harri J Marttila; Merja Marjamäki; Matti K Viljanen; Hanna Soini
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

8.  Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance.

Authors:  Florence Brossier; Nicolas Veziris; Chantal Truffot-Pernot; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

Review 9.  Diagnostic methods for tuberculosis.

Authors:  A Gupta; S K Sharma; J N Pande
Journal:  Indian J Chest Dis Allied Sci       Date:  1993 Apr-Jun

10.  Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam.

Authors:  Mai N T Huyen; Edine W Tiemersma; Nguyen T N Lan; Frank G J Cobelens; Nguyen H Dung; Dinh N Sy; Tran N Buu; Kristin Kremer; Pham T Hang; Maxine Caws; Richard O'Brien; Dick van Soolingen
Journal:  BMC Infect Dis       Date:  2010-06-03       Impact factor: 3.090

View more
  10 in total

1.  Performance of WHO-Endorsed Rapid Tests for Detection of Susceptibility to First-Line Drugs in Patients with Pulmonary Tuberculosis in Bangladesh.

Authors:  S M Mazidur Rahman; Md Fahim Ather; Rumana Nasrin; Mohammad Ariful Hoque; Razia Khatun; Tanjina Rahman; Mohammad Khaja Mafij Uddin; Shahriar Ahmed; Sayera Banu
Journal:  Diagnostics (Basel)       Date:  2022-02-05

2.  Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples.

Authors:  Abyot Meaza; Abebaw Kebede; Zelalem Yaregal; Zekarias Dagne; Shewki Moga; Bazezew Yenew; Getu Diriba; Helina Molalign; Mengistu Tadesse; Desalegn Adisse; Muluwork Getahun; Kassu Desta
Journal:  BMC Infect Dis       Date:  2017-04-17       Impact factor: 3.090

Review 3.  Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Ruvandhi R Nathavitharana; Patrick G T Cudahy; Samuel G Schumacher; Karen R Steingart; Madhukar Pai; Claudia M Denkinger
Journal:  Eur Respir J       Date:  2017-01-18       Impact factor: 16.671

Review 4.  Drug-resistant Spinal Tuberculosis.

Authors:  Anil K Jain; Karan Raj Jaggi; Himanshu Bhayana; Rumpa Saha
Journal:  Indian J Orthop       Date:  2018 Mar-Apr       Impact factor: 1.251

5.  Frequency of multi-drug resistance and mutations in Mycobacterium tuberculosis isolates from Punjab state of India.

Authors:  Ritu Singhal; Jyoti Arora; Grish C Sah; Manpreet Bhalla; Rohit Sarin; Vithal Prasad Myneedu
Journal:  J Epidemiol Glob Health       Date:  2017-05-24

6.  Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya.

Authors:  S A Aricha; L Kingwara; N W Mwirigi; L Chaba; T Kiptai; J Wahogo; J S Otwabe; P O Onyango; M Karanja; C Ayieko; S W Matu
Journal:  BMC Infect Dis       Date:  2019-10-15       Impact factor: 3.090

7.  Multicentric validation of indigenous molecular test Truenat™ MTB for detection of Mycobacterium tuberculosis in sputum samples from presumptive pulmonary tuberculosis patients in comparison with reference standards.

Authors:  N S Gomathi; Manjula Singh; Urvashi B Singh; V P Myneedu; D S Chauhan; Rohit Sarin; Anant Mohan; Anuj Bhatnagar; Jiten Singh Khangembam; T Kannan; M V V Rao; Jyoti Logani; Bindu Dey; Raman R Gangakhedkar; Soumya Swaminathan; Srikanth Tripathy
Journal:  Indian J Med Res       Date:  2020-10       Impact factor: 2.375

8.  Detection of multi-drug resistance & characterization of mutations in Mycobacterium tuberculosis isolates from North- Eastern States of India using GenoType MTBDRplus assay.

Authors:  Ritu Singhal; Vithal Prasad Myneedu; Jyoti Arora; Niti Singh; Girish Chander Sah; Rohit Sarin
Journal:  Indian J Med Res       Date:  2014-10       Impact factor: 2.375

9.  Impact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi, India.

Authors:  Neeta Singla; Srinath Satyanarayana; Kuldeep Singh Sachdeva; Rafael Van den Bergh; Tony Reid; Katherine Tayler-Smith; V P Myneedu; Engy Ali; Donald A Enarson; Digamber Behera; Rohit Sarin
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240

Review 10.  Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review.

Authors:  Thi Ngoc Anh Nguyen; Véronique Anton-Le Berre; Anne-Laure Bañuls; Thi Van Anh Nguyen
Journal:  Front Microbiol       Date:  2019-04-16       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.